Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

New Treatment Modalities for Allergic Disease

Introductions

Carlos E. Baena-Cagnani
F. Estelle Simons


Introduction

Carlos E. Baena-Cagnani

Dear Colleagues,

As President of World Allergy Organization (WAO), it is my pleasure to welcome you to the 23rd program in the World Allergy Forum (WAF) Symposium series: "New Treatment Modalities for Allergic Disease". A major role of WAO is to provide allergists with information about new treatments for allergic disease, about new indications for available therapies, and to look towards developments that may help us to better serve our patients in future. I thank our Member Society, the American Academy for Allergy, Asthma and Immunology, for hosting this symposium and for enabling us to bring this program to you today.

WAO is rapidly expanding and now represents 70 allergy and clinical immunology societies around the globe. We aim to encourage good practice in allergy at a global level, to provide a forum for allergists to share clinical and scientific expertise in allergy, and to promote our specialty worldwide. We work closely with our Member Societies to achieve these aims. WAO is now working with developing countries where national allergy societies have yet to be established. We are helping our colleagues in these countries to promote allergy and increase the awareness of allergic diseases, and collaborating with them on educational plans for health professionals.

Our educational activities are expanding. WAF, our longest running program, is presented at major international meetings, providing cutting edge symposia in clinical and scientific aspects of allergy. GLORIA Global Resources in Allergy, our educational program based on best clinical practice recommendations in different aspects of allergic disease, is presented at Member Societies' national meetings. Our liaison with World Health Organization on behalf of allergists worldwide has resulted in the Prevention of Allergy and Allergic Asthma document, to be published in 2004. We will work with WHO to promote the recommendations of this document at a global level. "A Revised Nomenclature for Allergy for Global Use", the report of the WAO Nomenclature Review Committee, is a global review based upon the EAACI Position Statement on Nomenclature of Allergy published in 2001. The report will be published in the Journal of Allergy and Clinical Immunology this year and will be widely promoted through our Web site www.worldallergy.org and through our educational programming.

These are just a few of the activities we are involved with on behalf of our members! As our activity base continues to expand, we hope you will find WAO becoming more and more relevant to your everyday practice.

Thank you for your participation in this WAO educational activity, I look forward to seeing you at the next World Allergy Forum in Amsterdam, June 2004. WAO sincerely recognizes the unrestricted educational grant provided by Novartis and Genentech to facilitate this event.

With my best regards,

Prof. Carlos E. Baena-Cagnani
President, World Allergy Organization
WAF Symposium Co-Chair


Introduction

F. Estelle Simons

Dear Colleagues,

On behalf of the World Allergy Organization, it is a great pleasure to welcome you to this World Allergy Forum, during which internationally renowned speakers will address the development of new treatment modalities for allergic disease.

At present, many, but not all, of our patients with asthma, allergic rhinitis and other allergic disorders can be effectively and safely treated with interventions such as glucocorticoids, ß2-adrenergic agonists, anti-leukotrienes, antihistamines, allergen avoidance and allergen-specific immunotherapy. Moreover, "successful treatment" generally means symptom control rather than true remission.

In 2003, immunomodulation with anti-IgE antibody injections was added to the therapeutic arsenal. Recently, studies of other interesting new immunomodulators have been conducted in humans. These include CpG-DNA-based vaccines, and antagonists of IL-4, IL-5, IL-9, IL-13, alpha-4 integrin, CD11a integrin, CD23, and CD25. The therapeutic index (benefit-to-risk ratio) of each of these new immunomodulators is being scrutinized carefully, and some of them likely represent clinically useful advances.

Our objectives for this World Allergy Forum are that, at the conclusion, we will be able to:

We look forward to excellent presentations from three outstanding researchers in these areas.

F. Estelle Simons, MD, FAAAAI
WAO Member-at-Large
WAF Symposium Co-Chair

 

Return to top
Return to WAF: San Francisco index